Welcome to our dedicated page for Vistagen Therapeutics SEC filings (Ticker: VTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing shouldn’t feel like decoding lab notes. Vistagen Therapeutics’ SEC documents run deep with neuroscience data, stem-cell platform details, and pivotal trial timelines—critical facts that can overwhelm even seasoned analysts.
Our platform solves that problem in three steps. First, real-time alerts surface every Vistagen Therapeutics insider trading Form 4 transactions notice, so you can track executive stock moves as they happen. Second, AI-powered summaries turn the 200-page Vistagen Therapeutics annual report 10-K simplified and each Vistagen Therapeutics quarterly earnings report 10-Q filing into a few clear paragraphs, highlighting cash runway, R&D spend, and key pipeline milestones. Third, expert context links each disclosure to what matters for an R&D-heavy business—whether it’s a licensing update in an 8-K material events explained alert or voting matters in the Vistagen Therapeutics proxy statement executive compensation section.
- Instant dashboards for Vistagen Therapeutics Form 4 insider transactions real-time
- AI commentary that answers common questions like “What does this toxicology update mean?” or “How do I read Vistagen Therapeutics SEC filings explained simply?”
- Side-by-side metrics to speed up Vistagen Therapeutics earnings report filing analysis
Whether you’re comparing segment spend across quarters or monitoring Vistagen Therapeutics executive stock transactions Form 4, Stock Titan turns raw disclosures into actionable intelligence—so you spend minutes, not hours, understanding Vistagen’s next scientific milestone.
Vistagen Therapeutics reported Q2 FY2026 results for the quarter ended September 30, 2025. Revenue was $258 thousand, while operating expenses rose to $20.3 million, driven by higher R&D ($15.9 million) and steady G&A ($4.4 million). The company posted a net loss of $19.4 million (basic and diluted net loss per share of $0.54).
Liquidity remained solid with cash, cash equivalents and marketable securities of $77.2 million as of September 30, 2025. Management concluded that “substantial doubt” exists about the company’s ability to continue as a going concern beyond twelve months from the financial statement issuance date.
Vistagen strengthened its balance sheet via its at-the-market program, selling 9,608,772 shares in the quarter for net proceeds of $27.9 million. Shares issued were 38,895,568 at September 30, 2025; as of November 12, 2025, 39,495,451 shares were outstanding. Deferred revenue totaled $2.5 million, primarily related to its AffaMed collaboration and Fuji Pharma negotiation agreement.
Vistagen Therapeutics (VTGN) reported a routine insider transaction. Director Paul R. Edick acquired 35,200 stock options on 10/27/2025 at an exercise price of $3.9 per share. The options were granted in connection with his appointment to the Board and were issued under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan.
The options vest in three equal annual installments beginning on the first anniversary of the grant date and expire on 10/27/2035. Following the transaction, 35,200 derivative securities were beneficially owned directly.
Vistagen Therapeutics (VTGN) filed a Form 3 initial statement of beneficial ownership. The reporting person is identified as a Director, with the event date of 10/27/2025.
The filing states that no securities are beneficially owned as of the event date. The form was filed by one reporting person and signed by Paul R. Edick.
Vistagen Therapeutics (VTGN)PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder.
The company attached a press release as Exhibit 99.1. The information was furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act.
Vistagen Therapeutics (VTGN) appointed Paul R. Edick to its Board of Directors effective October 27, 2025. He will serve until the next annual meeting or until a successor is elected, and he joins the Board’s Audit and Compensation Committees.
Under the Director Compensation Plan, Mr. Edick received stock options for 35,200 shares at an exercise price of $3.90 per share, equal to the closing price on his appointment date. The options have a 10-year term and vest in equal annual installments over three years starting on the one-year anniversary of the effective date. The company also entered into an Indemnification Agreement with Mr. Edick, providing indemnification to the fullest extent permitted under Nevada law and advancement of certain expenses.
Vistagen Therapeutics director Jon S. Saxe received a grant of non-qualified stock options. The Form 4 reports a grant of 17,600 options on 09/09/2025 with an exercise price of $3.61 and an expiration date of 09/09/2035. The filing shows 17,600 underlying shares beneficially owned following the transaction and lists the reporting persons relationship to the issuer as a Director. The grant was made under the issuers Amended and Restated 2019 Omnibus Equity Incentive Plan, and the options "vest in twelve equal monthly installments, beginning on the date of the grant," per the filing. The Form 4 was signed by an attorney-in-fact on 09/11/2025.
Vistagen Therapeutics director Mary L. Rotunno was granted a non-qualified stock option to buy 17,600 shares of common stock at an exercise price of $3.61. The option grant was reported with a transaction date of 09/09/2025 and a filing signature dated 09/11/2025. The options vest in twelve equal monthly installments beginning on the grant date and expire on 09/09/2035. The reporting person is identified as a director and the Form 4 was filed by one reporting person.
Margaret M. FitzPatrick, a director of Vistagen Therapeutics, Inc. (VTGN), was granted a non-qualified stock option on 09/09/2025 to purchase 17,600 shares of common stock at an exercise price of $3.61 per share. The option vests in twelve equal monthly installments beginning on the grant date, is exercisable immediately as installments vest, and expires on 09/09/2035. The filing reports the shares as directly beneficially owned following the grant, totaling 17,600 shares.
The Form 4 was submitted as a single reporting person filing and was signed by Cynthia Anderson as attorney-in-fact on 09/11/2025. No other transactions, cash proceeds, or derivative securities beyond this option grant are disclosed in the filing.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
